Show simple item record

dc.contributor.authorSacktor, N.
dc.contributor.authorNakasujja, N.
dc.contributor.authorSkolasky, R.
dc.contributor.authorRobertson, K.
dc.contributor.authorWong, M.
dc.contributor.authorMusisi, S.
dc.contributor.authorRonald, A.
dc.contributor.authorKatabira, E.
dc.date.accessioned2013-05-24T06:27:26Z
dc.date.available2013-05-24T06:27:26Z
dc.date.issued2006
dc.identifier.citationSacktor, N., Nakasujja, N., Skolasky, R., Robertson, K., Wong, M., Musisi, S., Ronald, A., Katabira, E. (2006). Antiretroviral therapy improves cognitive impairment in HIV individuals in sub-Saharan Africa. Neurology, 67(2) 311-314.en_US
dc.identifier.issn0028-3878
dc.identifier.urihttp://hdl.handle.net/10570/1374
dc.description.abstractAbstract—Background: Highly active antiretroviral therapy (HAART) can improve cognitive performance in some patients with HIV-associated cognitive impairment in the United States. The effect of HAART on HIV dementia in sub-Saharan Africa is largely unknown. Objective: To evaluate neuropsychological test and functional performance in HIV individuals after 3 and 6 months of HAART in Uganda. Methods: Twenty-three HIV individuals receiving HAART also received a detailed clinical history, neuropsychological testing, and a functional assessment. Follow-up evaluations were performed at 3 and 6 months after baseline. Longitudinal changes in the HIV dementia stage, the mean Z score for each neuropsychological test, and the Karnofsky Functional Performance Scale were evaluated at 3 and 6 months. Results: The mean (SD) CD4 cell count improved from 71 (15) at baseline to 161 (30) at 3 months (p 0.005) and 222 (46) at 6 months (p 0.001). Improvements were found in the Memorial Sloan Kettering HIV dementia stage and in tests of verbal memory, psychomotor speed, and executive functioning after 3 and 6 months of HAART (p 0.001 at 6 months for each neuropsychological test). There was also improvement in the Karnofsky Functional Performance Scale at both 3 and 6 months after the initiation of HAART (p 0.001). Conclusion: Highly active antiretroviral therapy (HAART) can be associated with improvement in neurocognitive and functional performance in HIV individuals in sub-Saharan Africa. These results suggest that HAART, if available in areas with limited resources in sub-Saharan Africa, should be provided for patients with HIV-associated cognitive impairment.en_US
dc.description.sponsorshipBill and Melinda Gates Foundation and Academic Alliance Foundation.en_US
dc.language.isoenen_US
dc.publisherAmerican Academy of Neurology (AAN)en_US
dc.subjectAntiretroviral therapyen_US
dc.subjectCognitive impairmenten_US
dc.subjectHIVen_US
dc.subjectSub-Saharan Africaen_US
dc.subjectHighly active antiretroviral therapyen_US
dc.subjectHAARTen_US
dc.subjectUgandaen_US
dc.titleAntiretroviral therapy improves cognitive impairment in HIV individuals in Sub-Saharan Africaen_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record